Immune drug trial offers hope for Tough-to-Treat Virus-Linked cancers
NCT ID NCT03258567
Summary
This study is testing the drug nivolumab to see if it can slow or stop the growth of certain cancers linked to the Epstein-Barr virus (EBV). It is for people aged 12 and older with EBV-positive lymphomas or lymphoproliferative disorders who have no standard therapy options or whose cancer has returned after treatment. Participants receive the drug by IV every four weeks for up to two years while doctors monitor their response and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.